BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35382836)

  • 1. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin.
    Liu H; Qiu C; Wang B; Bing P; Tian G; Zhang X; Ma J; He B; Yang J
    Front Cell Dev Biol; 2021; 9():619330. PubMed ID: 34012960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel.
    Sun M; Xu B; Chen C; Zhu Y; Li X; Chen K
    Clin Epigenetics; 2024 Feb; 16(1):25. PubMed ID: 38336771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fast, affordable and minimally-invasive diagnostic test for Cancer of Unknown Primary (CUP) using DNA methylation profiling.
    De Wilde J; Van Paemel R; De Koker A; Roelandt S; Van de Velde S; Callewaert N; Van Dorpe J; Creytens D; De Wilde B; De Preter K
    Lab Invest; 2024 Jun; ():102091. PubMed ID: 38830578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Profiling of CUP.
    Cancer Discov; 2016 Nov; 6(11):1203. PubMed ID: 27658716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues.
    Zhang S; He S; Zhu X; Wang Y; Xie Q; Song X; Xu C; Wang W; Xing L; Xia C; Wang Q; Li W; Zhang X; Yu J; Ma S; Shi J; Gu H
    Nat Commun; 2023 Sep; 14(1):5686. PubMed ID: 37709764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel.
    Bae JM; Ahn JY; Lee H; Jang H; Han H; Jeong J; Cho NY; Kim K; Kang GH
    Epigenomics; 2022 May; 14(10):615-628. PubMed ID: 35473295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
    Moran S; Martínez-Cardús A; Sayols S; Musulén E; Balañá C; Estival-Gonzalez A; Moutinho C; Heyn H; Diaz-Lagares A; de Moura MC; Stella GM; Comoglio PM; Ruiz-Miró M; Matias-Guiu X; Pazo-Cid R; Antón A; Lopez-Lopez R; Soler G; Longo F; Guerra I; Fernandez S; Assenov Y; Plass C; Morales R; Carles J; Bowtell D; Mileshkin L; Sia D; Tothill R; Tabernero J; Llovet JM; Esteller M
    Lancet Oncol; 2016 Oct; 17(10):1386-1395. PubMed ID: 27575023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
    Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
    Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.